Herbert Wertheim College of Medicine & Robert Stempel College of Public Health, Florida International University, Miami, FL, USA.
Unidad de Investigación Médica en Enfermedades Endocrinas, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Trials. 2022 Apr 4;23(1):253. doi: 10.1186/s13063-022-06177-0.
Providing optimal care for type 2 diabetes (DM2) patients remains a challenge for all healthcare systems. Patients often encounter various barriers in adhering to self-management programs due to lack of knowledge and understanding of self-care activities, lack of individualized and coordinated care, inconvenient and costly education sessions, and poor patient-provider communication. Mobile technologies such as cell phones/smartphones, handheld tablets, and other wireless devices offer new and exciting opportunities for addressing some of these challenges. The purpose of this study is to compare a diabetes management strategy using an information board and a mobile application versus standard care in patients with uncontrolled DM2.
The SANENT (Sistema de Análisis de Enfermedades No Transmisibles) trial is a primary care-based, prospective, two-arm, randomized controlled, open-label, blinded-endpoint study. We aim to recruit 1440 DM2 patients during a period of 6 months until the requested number of participants has been achieved. The total length of the intervention will be 1 year. Both men and women treated for DM2 with an HbA1c > 8.5% and ≥ 20 years of age are eligible to participate in the study. The primary outcome of the study is improved diabetes control measured by changes in HbA1c in the study participants. HbA1c will be measured at baseline, 3-month, 6-month, 9-month, and 12-month follow-up visits in all participants. The main analysis will be based on the intention-to-treat principle. The primary endpoint of the study will be the change in HbA1C within the groups and the differences between the groups. This will be assessed by a repeated measurement approach based on mixed models which contain both fixed effects and random effects.
The overall goal of this project is to contribute to the evidence for the use of mobile technology to improve the treatment and regulation of poorly controlled DM2 patients living in Mexico. Our proposed project will show how mobile health technology tools can be used in the treatment of patients with uncontrolled DM2 in primary health care in a Latin American population, and particularly how they could help diabetes patients take better care of themselves.
ClinicalTrials.gov , US National Institutes of Health NCT04974333 . Prospectively registered on July 13, 2021. Protocol version number 1, dated August 15th, 2021.
为 2 型糖尿病(DM2)患者提供最佳护理仍然是所有医疗保健系统面临的挑战。由于缺乏自我护理活动的知识和理解、缺乏个性化和协调的护理、教育课程不方便且昂贵、以及医患沟通不畅,患者在坚持自我管理计划方面经常会遇到各种障碍。移动技术,如手机/智能手机、掌上平板电脑和其他无线设备,为解决其中一些挑战提供了新的令人兴奋的机会。本研究的目的是比较使用信息板和移动应用程序的糖尿病管理策略与标准护理在未控制的 DM2 患者中的效果。
SANENT(非传染性疾病分析系统)试验是一项基于初级保健的前瞻性双臂随机对照开放标签盲终点研究。我们计划在 6 个月的时间内招募 1440 名 DM2 患者,直到达到要求的参与者人数。干预的总长度为 1 年。年龄在 20 岁及以上,糖化血红蛋白(HbA1c)>8.5%且接受 DM2 治疗的男性和女性均有资格参加本研究。该研究的主要结果是通过研究参与者的 HbA1c 变化来改善糖尿病控制。所有参与者在基线、3 个月、6 个月、9 个月和 12 个月随访时测量 HbA1c。主要分析将基于意向治疗原则。研究的主要终点是组内 HbA1C 的变化以及组间的差异。这将通过基于混合模型的重复测量方法进行评估,该方法包含固定效应和随机效应。
该项目的总体目标是为移动技术在改善墨西哥居住的治疗和控制不佳的 2 型糖尿病患者方面的应用提供证据。我们提出的项目将展示移动健康技术工具如何在拉丁美洲人群的初级保健中用于治疗未控制的 2 型糖尿病患者,特别是它们如何帮助糖尿病患者更好地照顾自己。
ClinicalTrials.gov,美国国立卫生研究院 NCT04974333。于 2021 年 7 月 13 日前瞻性注册。协议版本号 1,日期为 2021 年 8 月 15 日。